Background {#Sec1}
==========

Hepatitis B virus (HBV) is a DNA virus transmitted parenterally, sexually, and perinatally. HBV affects 350 to 400 million persons worldwide and constitutes a major global health burden \[[@CR1], [@CR2]\]. HBV infection can cause acute and chronic liver diseases including cirrhosis and hepatocellular carcinoma (HCC). Following immunosuppression, HBV replication along with signs of hepatocellular injury in a silent hepatitis B surface antigen (HBsAg) carrier may occur \[[@CR3]\]. The clinical presentation of HBV reactivation ranges from asymptomatic to severe fulminant hepatitis, liver failure, and death. HBV reactivation in cancer patients undergoing cytotoxic chemotherapy has been observed in patients with lymphoma \[[@CR4], [@CR5]\], patients treated with corticosteroids \[[@CR6], [@CR7]\] and rituximab \[[@CR8], [@CR9]\], as well as in patients undergoing stem cell and bone marrow transplantation \[[@CR10], [@CR11]\]. HBV has long been endemic in Taiwan, and, previously, the seropositive rates of hepatitis B core antibody (anti-HBc) approached 80%--90% and the carrier rate of HBsAg in the population reached a level as high as 15%--20% prior to the nationwide hepatitis B vaccination program \[[@CR12]--[@CR14]\].

Hematological malignancy is a group of clonal blood disorders that affect lymphoid, myeloid, and stem cells. The clinical manifestations of hematological malignancy usually present with anemia, thrombocytopenia, leukopenia, and varying degrees of immunocompromised status. Conventional cytotoxic chemotherapy is the major treatment for hematological malignancy. Immunotherapy, graft versus host disease, immunosuppressant, and stem cell transplantation also detract from immune functions and result in HBV reactivation \[[@CR4]--[@CR11]\]. Reactivation of viral hepatitis, including hepatitis B, is a potential cause for abnormal liver function tests in leukemic patients receiving chemotherapy \[[@CR15], [@CR16]\]. Various chemotherapy agents and steroids are frequently used as part of a combination regimen for hematological malignancy. HBV reactivation has been highlighted as being crucial for the treatment of lymphoma \[[@CR4]--[@CR6]\]. Several comprehensive guidelines have been proposed to provide evidence-based recommendations for clinicians caring for this patient population \[[@CR17]--[@CR22]\]. However, the epidemiology and clinical risk factors among different subtypes of hematological malignancy remain unclear. We previously investigated the epidemiology and clinical manifestations of hepatitis B reactivation among 490 acute myeloid leukemia (AML) patients \[[@CR23]\]. The incidence of hepatitis B reactivation among AML patients with HBV carriage was 9.5 per 100 person--years \[[@CR23]\]. Hepatitis B reactivation is not uncommon in HBsAg positive AML patients. In the present study, we investigated the epidemiology of HBV reactivation for varying subtypes of hematological malignancy and analyzed the risk factors among patients with different subtypes of hematological malignancy.

Methods {#Sec2}
=======

Hospital setting and patients {#Sec3}
-----------------------------

National Taiwan University Hospital (NTUH) is a 2900-bed teaching hospital in Taipei metropolitan area. The clinical characteristics, hepatitis B serology, hepatitis B virus DNA data, and outcome results of all adult patients with hematological malignancy during the period of January 2008 to December 2013 that attended NTUH were retrospectively reviewed and analyzed. Liver function tests, hepatitis B serology titer, and HBV DNA levels were performed as clinically indicated. This study was approved by the National Taiwan University Hospital Institutional Review Board.

Definitions {#Sec4}
-----------

The biochemistry alanine aminotransferase (ALT) was measured using the Beckman Coulter AU5800 platform (Beckman Coulter Inc., Brea, CA, USA); HBsAg, hepatitis B surface antibody (anti-HBs), anti-HBc, hepatitis B envelope antigen (HBeAg), and hepatitis C antibody (anti-HCV) were measured using the Abbott ARCHITECT i2000SR (Abbott Laboratories, Abbott Park, North Chicago, IL, USA); HBV DNA was analyzed using the COBAS® AmpliPrep /COBAS® TaqMan® HBV Test, v2.0 (Roche, Basel, Switzerland) in accordance with manufacturer instructions. The serological results were defined by the following cut-off values: HBsAg positive was ≧0.05 IU/mL; anti-HBs positive was a seroprotection threshold of 10mIU/ mL; and anti-HBc positive was ≧1.0 IU/mL. HBeAg positive was defined as ≧1.0 IU/mL. Chronic hepatitis B carrier status was defined by the detection of positive HBsAg counts for more than 6 months. Hepatitis B reactivation was defined as a greater than 10-fold increase, compared with previous nadir levels of HBV DNA, or by the reappearance of HBeAg in the serum for patients whose baseline HBeAg count was negative \[[@CR5], [@CR6]\]. HBV-related hepatitis was defined as a greater than 3-fold increase of the serum alanine aminotransferase (ALT) level (the upper normal limit is 41 IU/L at NTUH) accompanying or following HBV reactivation. In July 1984, the Taiwan government launched a nationwide universal HBV vaccination program \[[@CR13]\]. The following catch-up program of the nationwide HBV vaccination had a coverage rate of 86.9% to 98.0% \[[@CR14]\].

The diagnosis of cirrhosis was based on clinical symptoms and signs and imaging studies (ultrasound and computed tomography). The diagnostic criteria of HCC in this study were based on histologic and/or clinical findings and on the presence of the following: chronic viral hepatitis infection and liver cirrhosis, hepatic tumor with imaging (ultrasound and computed tomography) characteristics compatible with a diagnosis of HCC and without evidence of gastrointestinal or other primary tumor, and a persistent elevation of the serum level of alpha-fetoprotein to 400 ng/mL or higher.

Statistical analysis {#Sec5}
--------------------

The survival rates were estimated using the Kaplan-Meier analysis and compared using the log-rank test. Categorical variables were compared using the chi-square test. Univariate and multivariate analyses with a Cox regression analysis (log-rank test) were performed. Factors with *p*-values of ≤0.2 in univariate analysis were used in the multivariate model. All statistical analyses were performed using the statistical package SPSS for Windows v.18 (SPSS Inc., Chicago, IL). A *p*-value of ≤0.05 was considered significant and all statistical tests were two-tailed.

Results {#Sec6}
=======

Epidemiology {#Sec7}
------------

There were 2083 patients with hematological malignancy admitted to the hematological ward of the National Taiwan University Hospital between 2008 and 2013. The flow chart is illustrated in Fig. [1](#Fig1){ref-type="fig"}. A total of 1962 patients with hepatitis B serological profile at diagnosis of hematological malignancy were investigated, including 1046 men and 914 women. The median age was 55 years (range 15--97 years). The detailed clinical characteristics and laboratory data are listed in Table [1](#Tab1){ref-type="table"}. The most common diagnosis of hematological malignancy was lymphoma, with 769 people (39.2%), followed by acute myeloid leukemia (AML), with 606 people (30.9%), myeloma, with 197 people (10.0%), acute lymphoblastic leukemia (ALL), with 160 people (8.2%), myelodysplastic syndrome (MDS) or aplastic anemia (AA), with 142 people (7.2%), chronic myeloid leukemia (CML) or myeloproliferative neoplasm (MPN), with 60 people (3.1%), and chronic lymphocytic leukemia (CLL), with 27 people (1.4%). Of 1962 patients, 286 (14.6%) were diagnosed with positive HBsAg during their diagnosis of hematological malignancy. There were 174 of 286 HBsAg-positive patients had HBeAg data at diagnosis of malignancy. Positive Hbe and anti-Hbe rate were 21.3% (37 / 174) and 80.4% (107 / 133) in 286 HBV carriers. A total of 97 (33.9%) of 286 HBsAg-positive patients had HBV reactivation during follow-up. 71 (73.2%) of 97 patients with HBV reactivation developed hepatitis and the peak median alanine aminotransferase level is 613 IU/L (range 105--3506 IU/L). Ten patients died due to fulminant hepatitis and hepatic failure. For the median follow-up of 1050 days, the incidence of HBV reactivation in 286 HBV carriers was 10.4 per 100 person--years. The higher incidence value was 13.4 per 100 person--years for AML, and the lower was 7.4 per 100 person-years for CML/MPN, and there was no difference among people with varying subtypes of hematological malignancy (*p* = 0.335).Fig. 1Study flow and hepatitis B serological data of patients at diagnosis of hematological malignancyTable 1Clinical and laboratory data of patients with hematological malignancyTotalAMLALLLymphomaCML/MPNCLLMMMDS/AA*p*Number19626061607696027197143GenderMan1048326833993616108810.799Woman9142807737024118962Age, median(range), year55(15--97)54(17--92)38(16--86)57(15--97)48(18--86)61(37--89)59(30--87)55(17--94)\<0.001HBs Ag(+) at diagnosis28675131426531140.002HBV reactivation9729346121060.335HBs Ag(−) positive seroconversion41572401310.013Hepatitis C731704211570.013Liver cirrhosis21611010120.924Hepatocellular carcinoma930420000.038Underlying diabetes27375221098431240.833Allogeneic transplantation4392338148182354\<0.001*AML* acute myeloid leukemia, *ALL* acute lymphoblastic leukemia, *CML/MPN* chronic myeloid leukemia/myeloproliferative neoplasm, *CLL* chronic lymphocytic leukemia, *MM* myeloma, *MDS/AA* myelodysplastic syndrome/aplastic anemia

A total of 41 (2.4%) of 1676 patients whose HBsAg was negative initially displayed positive seroconversion during subsequent follow--ups and had their HBsAg become positive. Anti-HBc data existed for a total of 849 patients, and 567 (66.8%) patients showed positive anti-HBc in this cohort.

Prophylaxis of hepatitis B reactivation in patients with hematological malignancy {#Sec8}
---------------------------------------------------------------------------------

There were 286 patients with positive HBsAg at diagnosis of hematological malignancy. Of the 286 patients, the primary prophylaxis for 171 patients (59.8%) was antiviral agents, including 85 (49.7%) patients with entecavir, 76 (44.4%) with lamivudine, 2 (1.2%) with telbivudine, 1 (0.6%) with tenofovir, and 7 (4.1%) with adefovir. A total of 97 patients had HBV reactivation and 71 (73.2%) of the 97 patients had hepatitis. There were 59 patients who developed HBV reactivation after a discontinuance period of antiviral agent primary prophylaxis, and the median length for HBV reactivation was 210 days (range 15--2349 days) after discontinuing the antiviral drug. Even under antiviral drug use, 26 patients had HBV reactivation, including 6 who had tyrosine--methionine--aspartate-- aspartate mutation. There were 12 patients who had HBV reactivation without antiviral prophylaxis. A total of 10 (10.3%) out of 97 HBV reactivation patients died of fulminant hepatitis and hepatic failure, including 5 patients who had discontinued use of the antiviral drug (median period after discontinuance was 96 days, range 44--226 days), 3 patients who did not use antiviral prophylaxis, and 2 other patients with HBV reactivation even with use of antiviral prophylaxis.

Risk of HBV reactivation in HBV carrier {#Sec9}
---------------------------------------

We analyzed the risk factors of HBV reactivation in 286 HBsAg positive patients. The detailed results are listed in Table [2](#Tab2){ref-type="table"}. The variables comprised hematological malignancy subtypes, age, gender, concurrent hepatitis C infection, liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, allogeneic transplantation recipient, and antiviral prophylaxis use. A univariate analysis revealed that hepatocellular carcinoma (*p* = 0.032) and antiviral prophylaxis (*p* \< 0.001) were risk factors of HBV reactivation in an HBV carrier, and age \> 65 years was associated with a reduced rate of HBV reactivation (*p* = 0.052). A multivariate analysis revealed that both hepatocellular carcinoma (*p* \< 0.001, odds ratio (OR): 0.101, 95% confidence interval (CI): 0.029--0.355), and antiviral prophylaxis (*p* \< 0.001, OR: 4.631, 95% CI: 2.902--7.390) were independent risk factors of HBV reactivation in HBsAg-positive patients.Table 2Risk factors of HBV reactivation in HBsAg-positive patients with hematological malignancyFactorsReactivation\
*N* = 97No Reactivation\
*N* = 189Univariate\
*P* valueMultivariate\
*P* ValueOdds ratio(95% CI)Hematological malignancy0.332NA AML2946  ALL310  Lymphoma4696  CML/MPN15  CLL23  Myeloma1021  MDS/AA68Age \> 65 year0.0520.198 Yes1157 No86132Gender0.781NA Man55106 Woman4283Hepatitis C0.1800.453 Yes44 No93185Liver cirrhosis0.906NA Yes47 No93182Hepatocellular carcinoma0.032\<0.0010.101(0.029--0.355) Yes31 No94188Diabetes mellitus0.388NA Yes1020 No87169Allogeneic transplantation0.1130.269 Yes2831 No69158Antiviral prophylaxis\<0.001\<0.0014.631(2.902--7.390) Yes26145 No7144*AML* acute myeloid leukemia, *ALL* acute lymphoblastic leukemia, *CML/MPN* chronic myeloid leukemia/myeloproliferative neoplasm, *CLL* chronic lymphocytic leukemia, *MM* myeloma, *MDS/AA* myelodysplastic syndrome/aplastic anemia

Risk factor of hepatitis B reverse seroconversion {#Sec10}
-------------------------------------------------

We observed that 41 (2.4%) out of the 1676 patients who were HBsAg negative at diagnosis of hematological malignancy exhibited reverse seroconversion to HBsAg positive in the follow-up, including 7 (4.8%) out of 147 patients with ALL, 1 (4.5%) out of 22 with CLL, 24 (3.8%) out of 627 with lymphoma, 5 (0.9%) out of 531 with AML, 3 (1.8%) out of 166 with myeloma, and 1 (0.8%) out of 129 with MDS and AA, respectively. There were 54 patients with CML/MPN; however, out of them, no one acquired reverse seroconversion. The median follow--up period was 835 days (range 1--2976 days). A total of 36 (87.8%) out of 41 patients had hepatitis after reverse seroconversion, and 1 patient died of fulminant hepatitis and hepatic failure. The detailed results are provided in Table [3](#Tab3){ref-type="table"}.Table 3Risk factors for positive seroconversion of HBsAg in HBsAg-negative patients detected during diagnosis of hematological malignancyPositive\
Sero-\
conversion\
(*n* = 41)No\
conversion (*n* = 1635)Univariate\
*P* valueMultivariate *P* valueOdds ratio\
(95% CI)Age0.174NA ≧65 years12466  \< 65 years291169Gender0.737NA Men22866 Women19769Hematological malignancy0.0380.084NA AML5526 ALL7140 Lymphoma24603 CML/MPN054 CLL121 Myeloma3163 MDS / AA1128Diabetes mellitus0.0400.0050.218(0.076--0.629) Yes10233 No311402Allogeneic transplantation0.1160.0130.182(0.047--0.701) Yes15365 No261270Liver cirrhosis\<0.001\<0.0010.002(0.000--0.047) Yes28 No391627Hepatocellular carcinoma0.748NA Yes05 No411630Hepatitis C0.216NA Yes065 No411570Negative Anti-HBs Antibody^a^0.237NA Yes10304 No241157Low Anti-HBs Antibody ^a^0.0020.0160.020(0.001--0.480) Yes30915 No4546Positive Anti-HBc Antibody^b^0.0050.0130.070(0.009--0.571) Yes18567 No1263*NA* not available, ^a^ Anti-HBs Antibody checked, (*n* = 1495), Low Anti-HBs Antibody \<100mIU/mL, ^b^ Anti-HBc Antibody checked (*n* = 849), *AML* acute myeloid leukemia, *ALL* acute lymphoblastic leukemia, *CML/MPN* chronic myeloid leukemia/myeloproliferative neoplasm, *CLL* chronic lymphocytic leukemia, *MM* myeloma, *MDS/AA* myelodysplastic syndrome/aplastic anemia

We analyzed the risk of reverse seroconversion in 1676 patients with hematological malignancy. The variables comprised hematological malignancy subtypes, age, gender, concurrent hepatitis C infection, liver cirrhosis, hepatocellular carcinoma, diabetes mellitus, allogeneic transplantation recipient, anti-HBs, and anti-HBc. A univariate analysis revealed that hematological subtypes (*p* = 0.038), diabetes mellitus (*p* = 0.04), liver cirrhosis (*p* \< 0.001), low anti-HBs titer values (*p* = 0.002), and positive anti-HBc (*p* = 0.005) were risk factors of HBsAg positive seroconversion. A multivariate analysis revealed that diabetes mellitus (*p* = 0.005, OR: 0.218, 95% CI: 0.076--0.629), allogeneic transplantation (*p* = 0.013, OR: 0.182, 95% CI: 0.047--0.701), liver cirrhosis (*p* \< 0.001, OR: 0.002, 95% CI: 0.000--0.047), low anti-HBs titer values (*p* = 0.016, OR: 0.020, 95% CI: 0.001--0.480), and positive anti-HBc (*p* = 0.013, OR: 0.070, 95% CI: 0.009--0.571) were independent risk factors of HBsAg positive seroconversion. Having different subtypes of hematological malignancy had no impact on HBsAg positive seroconversion in patients.

Discussion {#Sec11}
==========

HBV is endemic in Taiwan. Mass vaccination started in 1984 \[[@CR13], [@CR14]\]. However, the prevalence of HBV is still high in the general population. This is the first large cohort study to compare the incidence of HBV reactivation in different subtypes of hematological malignancy. In this retrospective cohort, 286 (14.6%) of 1962 patients were HBV carriers. HBV reactivation is critical for the clinical care of patients with hematological malignancy receiving chemotherapy. The incidence of HBV reactivation was 10.4 per 100 person--years in this study. This epidemiological result is similar to those of previous studies of lymphoma (10.4 per 100 person--years) \[[@CR5]\] and AML (9.5 per 100 person--years) \[[@CR23]\].

HBV reactivation in cancer patients receiving cytotoxic chemotherapy has been noted for 3 decades \[[@CR3], [@CR24], [@CR25]\], especially in patients with lymphoma \[[@CR4], [@CR5]\], patients treated with corticosteroids \[[@CR6], [@CR7]\] and rituximab \[[@CR8], [@CR9]\], as well as in patients undergoing stem cell and bone marrow transplantation \[[@CR10], [@CR11]\]. There have been some reports concerning HBV reactivation in patients with AML \[[@CR23], [@CR26], [@CR27]\] and myeloma \[[@CR28], [@CR29]\]. We observed HBV reactivation in patients with different subtypes of hematological malignancy. This study confirmed that HBV reactivation developed in patients with different subtypes of hematological malignancy. Antiviral drug prophylaxis is critical for HBV reactivation according to most guidelines and professional consensuses \[[@CR17]--[@CR22]\]. In the studied cohort, 59 (60.8%) out of 97 HBV carriers experienced HBV reactivation after discontinuing use of antiviral medication. Thus, the ideal length that HBV patients should use antiviral medication for after chemotherapy is still a controversial topic.

Resolved hepatitis B reactivation and acquired reverse seroconversion has been investigated in recent literature \[[@CR30]--[@CR33]\]. In one such study, 33 (6.8%) out of 482 lymphoma patients acquired HBV reverse seroconversion between 2000 and 2010 \[[@CR33]\]. HBV reverse seroconversion patients typically receive more cycles (≥6), prolonged durations of rituximab therapy, and hematopoietic stem cell transplantation than non-HBV reverse seroconversion patients do. In the present studied cohort, we observed that 41 (2.4%) of out 1676 patients acquired HBV reverse seroconversion. There were 54 patients with CML/MPN; however, out of these patients no one acquired reverse seroconversion. We also observed that HBV reverse seroconversion could be observed in patients with other subtypes of hematological malignancy other than lymphoma. Diabetes mellitus, allogeneic transplantation, liver cirrhosis, low anti-HBs titers (less than 100 mI U/mL), and positive anti-HBc were independent risk factors of HBV reverse seroconversion.

Diabetes mellitus is an immunocompromised status and may trigger spontaneous HBV reactivation \[[@CR34]--[@CR36]\]. The anti-HBc positive rate was 69% in this study. All patients with HBV reverse seroconversion displayed negative anti-HBc serology. Because the rate of HBV reverse seroconversion was 2.4% in this cohort, treating all resolved HBV patients receiving chemotherapy in Taiwan does not seem likely. The high risk factors of a stratified risk comprise diabetes mellitus, allogeneic transplantation, liver cirrhosis, low anti-HBs titers (less than 100 mIU/mL), and positive anti-HBc. Thus, predicting the risk of HBV reverse seroconversion is possible.

Conclusions {#Sec12}
===========

The treatment of hematological malignancy has improved during the past several decades. Conventional cytotoxic chemotherapy, rituximab-based immunotherapy, and stem cell transplantation can cause a patient to become immunocompromised and result in HBV reactivation. We observed that HBV carriers and patients with resolved HBV could experience reverse seroconversion and reactivation. The incidence of HBV reactivation did not differ significantly among various subtypes of hematological malignancy. Antiviral agent prophylaxis is the most critical method to prevent HBV reactivation. However, some patients develop HBV reactivation after discontinuing use of antiviral agents after chemotherapy. Thus, the duration of antiviral agent treatment after chemotherapy should be further investigated.
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